Elosulfase alfa, injection
Products billed under this code include Vimizim.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vimizim.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vimizim | BioMarin Pharmaceutical Inc. | 68135-0100-01 | 5 | $1,603.905 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $320.781 | +$1.264 | 1 MG | Elosulfase alfa, injection | v1, posted September 17, 2026 |
| 3Q26 | $319.517 | +$7.571 | 1 MG | Elosulfase alfa, injection | v1, posted September 15, 2026 |
| 2Q26 | $311.946 | +$0.006 | 1 MG | Elosulfase alfa, injection | v1, posted September 15, 2026 |
| 1Q26 | $311.94 | +$3.257 | 1 MG | Elosulfase alfa, injection | v1, posted September 15, 2026 |
| 4Q25 | $308.683 | +$1.888 | 1 MG | Elosulfase alfa, injection | v1, posted September 8, 2026 |
| 3Q25 | $306.795 | +$12.86 | 1 MG | Elosulfase alfa, injection | v1, posted March 10, 2026 |
| 2Q25 | $293.935 | +$0.011 | 1 MG | Elosulfase alfa, injection | v1, posted March 10, 2026 |
| 1Q25 | $293.924 | +$0.008 | 1 MG | Elosulfase alfa, injection | v1, posted December 19, 2025 |
| 4Q24 | $293.916 | +$5.379 | 1 MG | Elosulfase alfa, injection | v1, posted June 11, 2025 |
| 3Q24 | $288.537 | +$5.313 | 1 MG | Elosulfase alfa, injection | v1, posted June 11, 2025 |
| 2Q24 | $283.224 | +$2.315 | 1 MG | Elosulfase alfa, injection | v1, posted March 11, 2025 |
| 1Q24 | $280.909 | −$0.013 | 1 MG | Elosulfase alfa, injection | v1, posted December 19, 2024 |
| 4Q23 | $280.922 | +$0.796 | 1 MG | Elosulfase alfa, injection | v1, posted October 10, 2024 |
| 3Q23 | $280.126 | +$17.417 | 1 MG | Elosulfase alfa, injection | v1, posted June 5, 2024 |
| 2Q23 | $262.709 | −$0.013 | 1 MG | Elosulfase alfa, injection | v1, posted February 23, 2024 |
| 1Q23 | $262.722 | +$0.048 | 1 MG | Elosulfase alfa, injection | v1, posted December 6, 2023 |
| 4Q22 | $262.674 | +$0.366 | 1 MG | Elosulfase alfa, injection | v1, posted June 22, 2023 |
| 3Q22 | $262.308 | +$12.013 | 1 MG | Elosulfase alfa, injection | v1, posted June 9, 2023 |
| 2Q22 | $250.295 | −$0.007 | 1 MG | Elosulfase alfa, injection | v1, posted December 14, 2022 |
| 1Q22 | $250.302 | −$0.027 | 1 MG | Elosulfase alfa, injection | v1, posted June 8, 2022 |
| 4Q21 | $250.329 | +$0.209 | 1 MG | Elosulfase alfa, injection | v1, posted June 2, 2022 |
| 3Q21 | $250.12 | +$4.776 | 1 MG | Elosulfase alfa, injection | v1, posted June 2, 2022 |
| 2Q21 | $245.344 | +$0.002 | 1 MG | Elosulfase alfa, injection | v1, posted March 1, 2022 |
| 1Q21 | $245.342 | – | 1 MG | Elosulfase alfa, injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.